How many clinical trials are there for Immunoproliferative Disorders?

PlainTrial tracks 5 US clinical trials for Immunoproliferative Disorders, of which 0 are currently recruiting.

Which interventions appear most often on Immunoproliferative Disorders trial records?

Fludarabine is the most-linked intervention name on Immunoproliferative Disorders records (3 trial links), followed by Bendamustine. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Immunoproliferative Disorders?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Immunoproliferative Disorders: early-phase trial registry

Compiled by PlainTrial · August 8, 2026

A small indexed set (5 trials) with no open enrollment listed right now.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Browse conditions → How counts are built

5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count

Immunoproliferative Disorders: 5 US clinical trials tracked, none currently recruiting.

Immunoproliferative Disorders is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is UNC Lineberger Comprehensive Cancer Center, running 5 of these trials.

Enrollment posture brief

Registry condition immunoproliferative-disorders

Volume-matched condition peers

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Open-enrollment share among volume-matched conditions near Immunoproliferative Disorders

Immunoproliferative Disorders has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Immunoproliferative Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Immunoproliferative Disorders is recruiting below its size-band peers.

0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
One sponsor concentrates Immunoproliferative Disorders research.

UNC Lineberger Comprehensive Cancer Center accounts for 5 of 5 trials (100%). 1 distinct sponsors appear on at least one study for this condition label.
Most Immunoproliferative Disorders trials plan to enrol fewer than 100 people.

Median target enrolment is 19 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
Immunoproliferative Disorders research is mostly interventional.

5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.